GUT Inc. targets tissue remodeling and fibrosis, key drivers of structural damage of the inflamed bowel in Inflammatory bowel disease (IBD)
GUT Inc. focuses on the clinical development of RNA oligonucleotides in IBD. We and others have shown that intestinal fibrosis, which is characterized by excessive deposition of extracellular matrix (ECM) components by activated cells of mesenchymal origin in the intestinal wall, is the basis of several gastrointestinal disorders, in particular IBD. By systematically addressing the factors that mediate fibrosis we have been able to identify mechanistically-driven novel approaches that have now been translated into positive clinical outcomes in IBD. We have completed successful Phase IIa clinical trial in Ulcerative Colitis.
GUT Inc. is pleased to announce that the abstract of IIT study results with GUT-1 has been accepted as “Moderated Poster Presentation” at the UEG Week (Copenhagen in October 14-17).